To the full analysis
Shanghai Fosun Pharmaceutical (Group) stock: growth
600196.SSShanghai Fosun Pharmaceutical (Group) reported $6.22B in revenue for fiscal 2025, up 1.1% on the prior year, up 6.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13%
per year from 2006 to 2025, per share 10.4%
Earnings (Annual rate)
14.5%
per year from 2006 to 2025, per share 11.9%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.5% | 12.7% | 13.0% |
| Revenue per share | 5.8% | 11.1% | 10.4% |
| Earnings | −1.6% | 3.2% | 14.5% |
| Earnings per share | −2.3% | 1.7% | 11.9% |
| Free cash flow | no data | 15.0% | no data |
| Free cash flow per share | no data | 13.4% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $612.17M | $38.86M | −$12.25M |
| 2007 | $553.86M | $93.84M | −$11.73M |
| 2008 | $565.85M | $103.6M | $3.36M |
| 2009 | $577.41M | $374.64M | −$12.93M |
| 2010 | $683.15M | $129.52M | −$20.37M |
| 2011 | $972.6M | $174.8M | −$72.01M |
| 2012 | $1.1B | $234.53M | −$74.24M |
| 2013 | $1.5B | $237.33M | −$4.26M |
| 2014 | $1.8B | $316.85M | $12.11M |
| 2015 | $1.89B | $368.93M | $57.81M |
| 2016 | $2.19B | $420.77M | $28.2M |
| 2017 | $2.78B | $468.56M | $61.43M |
| 2018 | $3.74B | $406.09M | −$33.71M |
| 2019 | $4.29B | $498.12M | −$110.92M |
| 2020 | $4.54B | $549.29M | −$278.54M |
| 2021 | $5.85B | $709.14M | −$153.54M |
| 2022 | $6.59B | $559.49M | −$250.63M |
| 2023 | $6.21B | $357.85M | −$288.3M |
| 2024 | $6.16B | $415.38M | $10.02M |
| 2025 | $6.22B | $505.46M | $233.47M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 13 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.